9.12  0.26 (2.93%)		03-19 16:00
Open: 8.97 High: 9.465 Volume: 907,697		Pre. Close: 8.86 Low: 8.89 Market Cap: 540(M)

Short term
Mid term
Targets	6-month :	11.64	1-year :	12.54
Resists	First :	9.97	Second :	10.74
Pivot price	9.24
Supports	First :	8.72	Second :	7.25
MAs	MA(5) :	8.89	MA(20) :	9.51
	MA(100) :	11.51	MA(250) :	11.65
MACD	MACD :	-0.5	Signal :	-0.5
%K %D	K(14,3) :	13.6	D(3) :	7.9
RSI	RSI(14): 38.2
52-week	High :	15.13	Low :	8.72

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ EMBC ] has closed above bottom band by 42.8%. Bollinger Bands are 8.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	9.47 - 9.52	9.52 - 9.56
Low:	8.78 - 8.83	8.83 - 8.88
Close:	9.04 - 9.12	9.12 - 9.19

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.

Thu, 19 Mar 2026
Embecta - An Interesting Deal At An Interesting Time (NASDAQ:EMBC) - Seeking Alpha

Thu, 19 Mar 2026
Embecta (NASDAQ:EMBC) Trading 4.5% Higher - Time to Buy? - MarketBeat

Thu, 19 Mar 2026
Embecta to acquire Owen Mumford for up to £150 million - Investing.com

Thu, 19 Mar 2026
Embecta bets up to £150M to expand from diabetes care into drug delivery - Stock Titan

Tue, 17 Mar 2026
Embecta Corp. (NASDAQ:EMBC) Sees Large Increase in Short Interest - MarketBeat

Fri, 13 Mar 2026
BTIG Lowers PT on Embecta Corp. (EMBC) to $25, Keeps a Buy Rating - MSN

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	59 (M)
Shares Float	58 (M)
Held by Insiders	1.6 (%)
Held by Institutions	101.5 (%)
Shares Short	4,030 (K)
Shares Short P.Month	3,830 (K)

EPS	2.35
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-10.36
Profit Margin	12.9 %
Operating Margin	29.2 %
Return on Assets (ttm)	18.3 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	-0.4 %
Gross Profit (p.s.)	11.51
Sales Per Share	18.23
EBITDA (p.s.)	6.19
Qtrly Earnings Growth	0 %
Operating Cash Flow	214 (M)
Levered Free Cash Flow	189 (M)

PE Ratio	3.86
PEG Ratio	0
Price to Book value	-0.89
Price to Sales	0.5
Price to Cash Flow	2.52

Dividend	0.15
Forward Dividend	0
Dividend Yield	1.6%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.